(15:18 GMT) Kymera Therapeutics Price Target Raised to $136.00/Share From $116.00 by Truist Securities
Dow Jones Newswires
Kymera Therapeutics Is Maintained at Buy by Truist Securities
- Sources
- Dow Jones Newswires
- Markets
- Stocks
- Active symbols
- NASDAQ:KYMR
- Language
- English